Observational cross-sectional study evaluating the sociodemographic and clinical characteristics of patients with metastatic melanoma harboring a BRAF V600 mutation, treated with cobimetinib and vemurafenib based on routine clinical practice.

Maria Carmen Álamo de la Gala,Sebastian Ochenduszko,G. Crespo,Mónica Corral,Juana Maria Oramas Rodriguez,Maria Pilar Sancho,Javier Medina,Fernando Garicano Goldaraz,Pedro López Leiva,Begona Campos Balea,Analia Adela Rodriguez,Eva Muñoz-Couselo

Observational cross-sectional study evaluating the sociodemographic and clinical characteristics of patients with metastatic melanoma harboring a BRAF V600 mutation, treated with cobimetinib and vemurafenib based on routine clinical practice.

2020

Maria Carmen Álamo de la Gala
Sebastian Ochenduszko
G. Crespo
Mónica Corral
Juana Maria Oramas Rodriguez
Maria Pilar Sancho
Javier Medina
Fernando Garicano Goldaraz
Pedro López Leiva
Begona Campos Balea
Analia Adela Rodriguez
Eva Muñoz-Couselo

e22028Background: The drug combination of BRAF inhibitors with MEK inhibitors delays the onset of resistance and enhances apoptosis. Objectives: The main objective was to evaluate the percentage of...

Keywords:

Cobimetinib
Oncology
Internal medicine
routine clinical practice
Vemurafenib
Observational study
Pathology
Cross-sectional study
BRAF V600 Mutation
metastatic melanoma
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations